Scilex Holding Company operates as a pharmaceutical firm focused on the development and commercialization of innovative non-opioid pain management products. Its primary purpose is to address the unmet needs in pain relief while reducing the reliance on opioid medications, which are often associated with addiction and adverse effects. Scilex's flagship product, ZTlido®, is a lidocaine topical system designed for pain relief in patients suffering from postherpetic neuralgia.

Through its innovative approach to pain management, Scilex impacts several sectors within the healthcare industry, including pharmaceuticals, biotechnology, and medical devices. The company's offerings aim to provide effective, localized pain relief with improved delivery mechanisms, catering to a wide range of patients.

Scilex Holding Company plays a notable role in the pharmaceutical market by addressing the critical issue of pain management, offering alternatives to opioid treatments. Its commitment to advancing non-opioid therapeutics represents a significant shift in how chronic pain is managed, contributing to the healthcare sector's efforts to combat the opioid crisis and improve patient outcomes.